BACKGROUND: The feasibility and safety of a pumpless arteriovenous extracorporeal lung assist system (pECLA) has been demonstrated in previous studies of patients with severe respiratory insufficiency. The aim of this report was to examine whether pECLA is feasible in a center that is new to the technology and to determine the positive and adverse effects associated with its use. METHODS: This was a retrospective case series of 13 consecutive patients with established acute respiratory distress syndrome (ICU patients with ARDS or ALI) at a university hospital. Management consisted of transcutaneous placement of a femoral arteriovenous pECLA to allow lung-protective ventilation. Nonparametric statistics were applied; all data are values and standard deviations (SD). RESULTS: Mean simplified acute physiology score (SAPS) II was 49.5 (26); ICU mortality was 54% (7/13). Mean length of ICU stay was 34.5 (65.3) days for survivors (S) and 36 (32.8) days for non-survivors (NS). Total time on arteriovenous pECLA was 12.0 (22.2) days (S) and 7.0(7.8) days (NS), total time on mechanical ventilation was 31.0 (28.2) (S) and 32.0 (15.2) days (NS). Hypercapnia was significantly (P<0.05) reduced from 80.0 (23.0) (pre-pECLA) to 48.0 (13.0) mmHg (day 7), as were minute ventilation and inspiratory pressure. pECLA was accompanied by a significant (P<0.05) increase in the PaO2/fraction of inspired oxygen (P/F) ratio from 100.0 (28.9) (pre-pECLA) to 191.1 (114.3) mmHg after 7 days of treatment. Major complications were two inadvertent decannulations in the first two patients treated; there was one minor bleeding event in a patient seen subsequently. CONCLUSION: pECLA is an effective and manageable technique to support gas exchange in ARDS patients. This retrospective case series demonstrates the feasibility of pECLA in a center that did not have prior experience with this technique. pECLA may decrease further lung injury by minimizing the amount of time for which the lung is exposed to high stress and/or strain.
BACKGROUND: The feasibility and safety of a pumpless arteriovenous extracorporeal lung assist system (pECLA) has been demonstrated in previous studies of patients with severe respiratory insufficiency. The aim of this report was to examine whether pECLA is feasible in a center that is new to the technology and to determine the positive and adverse effects associated with its use. METHODS: This was a retrospective case series of 13 consecutive patients with established acute respiratory distress syndrome (ICU patients with ARDS or ALI) at a university hospital. Management consisted of transcutaneous placement of a femoral arteriovenous pECLA to allow lung-protective ventilation. Nonparametric statistics were applied; all data are values and standard deviations (SD). RESULTS: Mean simplified acute physiology score (SAPS) II was 49.5 (26); ICU mortality was 54% (7/13). Mean length of ICU stay was 34.5 (65.3) days for survivors (S) and 36 (32.8) days for non-survivors (NS). Total time on arteriovenous pECLA was 12.0 (22.2) days (S) and 7.0(7.8) days (NS), total time on mechanical ventilation was 31.0 (28.2) (S) and 32.0 (15.2) days (NS). Hypercapnia was significantly (P<0.05) reduced from 80.0 (23.0) (pre-pECLA) to 48.0 (13.0) mmHg (day 7), as were minute ventilation and inspiratory pressure. pECLA was accompanied by a significant (P<0.05) increase in the PaO2/fraction of inspired oxygen (P/F) ratio from 100.0 (28.9) (pre-pECLA) to 191.1 (114.3) mmHg after 7 days of treatment. Major complications were two inadvertent decannulations in the first two patients treated; there was one minor bleeding event in a patient seen subsequently. CONCLUSION: pECLA is an effective and manageable technique to support gas exchange in ARDSpatients. This retrospective case series demonstrates the feasibility of pECLA in a center that did not have prior experience with this technique. pECLA may decrease further lung injury by minimizing the amount of time for which the lung is exposed to high stress and/or strain.
Authors: Stefan Kluge; Stephan A Braune; Markus Engel; Axel Nierhaus; Daniel Frings; Henning Ebelt; Alexander Uhrig; Maria Metschke; Karl Wegscheider; Norbert Suttorp; Simone Rousseau Journal: Intensive Care Med Date: 2012-07-27 Impact factor: 17.440
Authors: Michael C Sklar; Francois Beloncle; Christina M Katsios; Laurent Brochard; Jan O Friedrich Journal: Intensive Care Med Date: 2015-06-25 Impact factor: 17.440
Authors: Jonathan D Marhong; Laveena Munshi; Michael Detsky; Teagan Telesnicki; Eddy Fan Journal: Intensive Care Med Date: 2015-03-10 Impact factor: 17.440
Authors: Stephan Braune; Susanne Kienast; Johannes Hadem; Olaf Wiesner; Dominic Wichmann; Axel Nierhaus; Marcel Simon; Tobias Welte; Stefan Kluge Journal: Intensive Care Med Date: 2013-07-27 Impact factor: 17.440
Authors: Andrey V Kozlov; Soheyl Bahrami; Enrico Calzia; Peter Dungel; Lars Gille; Andrey V Kuznetsov; Jakob Troppmair Journal: Ann Intensive Care Date: 2011-09-26 Impact factor: 6.925
Authors: Thomas Bein; Steffen Weber-Carstens; Anton Goldmann; Thomas Müller; Thomas Staudinger; Jörg Brederlau; Ralf Muellenbach; Rolf Dembinski; Bernhard M Graf; Marlene Wewalka; Alois Philipp; Klaus-Dieter Wernecke; Matthias Lubnow; Arthur S Slutsky Journal: Intensive Care Med Date: 2013-01-10 Impact factor: 17.440
Authors: Marianne Fitzgerald; Jonathan Millar; Bronagh Blackwood; Andrew Davies; Stephen J Brett; Daniel F McAuley; James J McNamee Journal: Crit Care Date: 2014-05-15 Impact factor: 9.097